Sara M. Tolaney, MD, MPH:T-DM1 is an antibody drug conjugate that consists of trastuzumab linked to emtansine. Emtansine is a very potent antimicrotubule agent. When this antibody drug conjugate binds to HER2,it gets taken in intracellularly, and then the linker releases the emtansine intracellularly, resulting in cell death. So it’s a very clever mechanism to deliver very potent chemotherapy into the cancer cell. I think some people like to think of these antibody drug conjugates as smart bombs because of their very targeted delivery of chemotherapy.
Given data from KATHERINE, I do think that any patient who has residual disease after trastuzumab-based chemotherapy should be offered 14 cycles of TDM-1 because, again, it was associated with a 50% reduction in invasive disease-free survival events. I do think it also makes us realize the importance of giving therapy in the preoperative setting, because it allows us to better understand response to therapy and then tailor adjuvant treatment based on this response. Prior to KATHERINE people weren’t uniformly giving patients with locally advanced HER2-positive disease preoperative treatment. We knew data that suggested that preoperative therapy yielded similar outcomes to adjuvant therapy, and so we didn’t feel like we had to give the therapy in the preoperative setting. But now seeing that we can tailor treatment based on response to preoperative therapy, I think it should push us to utilize treatment preoperatively, particularly for those patients who have tumors larger than 2 cm, or who have clinically lymph node-positive disease.
Transcript edited for clarity.
Case: A 49-Year-Old Woman With HER2+ Breast Cancer
H & P
Imaging
Biopsy and labs:
Treatment
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More